SBIR/STTR Research Award
SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response
Award amount
$256,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- ONECYTE BIOTECHNOLOGIES INC
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-02-28
- UEI
- ERE5JFD78JB9
- Solicitation number
- Not reported
- Topic code
- BT
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to address a key challenge in the response to COVID-19, namely manufacturing sufficient quantities of novel therapeutics and vaccines. This proj
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II:A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development
- A proprietary single-cell analytics platform for accelerating biologics manufacturing
- SBIR Phase I: A High Throughput Microfluidics Platform to Measure Secretion from Single Cells
Research funding history
4 SBIR/STTR records share this UEI (2018–2023). Reported award amounts total $3,180,467. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: National Science Foundation, Department of Health and Human Services